Literature DB >> 25708220

Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.

Florent Malard1, Noel Milpied2, Didier Blaise3, Patrice Chevallier4, Mauricette Michallet5, Bruno Lioure6, Laurence Clément7, Yosr Hicheri8, Catherine Cordonnier9, Anne Huynh10, Ibrahim Yakoub-Agha11, Regis Peffault de Latour12, Mohamad Mohty13.   

Abstract

This retrospective report compared the 4-year outcomes of allogeneic stem cell transplantation (allo-SCT) in 651 adult patients with acute myeloid leukemia receiving a reduced-intensity (RIC) or nonmyeloablative conditioning (NMA) regimen according to the type of unrelated donors. These were either umbilical cord blood (UCB, n = 205), a 9/10 mismatched unrelated donor (MisMUD, n = 99), or a 10/10 matched unrelated donor (MUD, n = 347) graft. Neutrophil recovery was slower in UCB (74.5% by day 42) compared with MisMUD (94.8%) and MUD (95.6%) (P < .001). There was no significant difference in nonrelapse mortality between UCB and both MUD (hazard ratio [HR], 1.05; 95% confidence interval [CI], .62 to 1.78; P = .85) and MisMUD (HR, 1.58; 95% CI, .88 to 2.83; P = .13) The relapse/progression was similar between UCB and MisMUD (HR, .62; 95% CI, .37 to 1.03; P = .07), but was significantly lower in MUD compared with UCB (HR, .60; 95% CI, .39 to .92; P = .02). The rate of extensive chronic graft-versus-host disease (GVHD) was similar between UCB and both MUD (HR, 2.15; 95% CI, .93 to 4.97; P = .08) and MisMUD (HR, 1.84; 95% CI, .68 to 4.95; P = .23). The rate of severe grade III and IV acute GVHD was significantly increased in MisMUD compared with UCB (HR, 2.61; 95% CI, 1.30 to 5.23; P = .007). There was no significant difference in overall survival between UCB and both MisMUD (HR, .98; 95% CI, .66 to 1.45; P = .92) and MUD (HR, .74; 95% CI, .52 to 1.03; P = .08). These data suggest that in the setting of RIC/NMA, allo-SCT UCB is a valid alternative graft source, with significantly less chronic GVHD, compared with MisMUD, when there is no MUD available or when urgent transplantation is needed.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  10/10 Matched unrelated donor; 9/10 Mismatched unrelated donor; Acute myeloid leukemia; Allogeneic stem cell transplantation; Nonmyeloablative conditioning; Reduced-intensity conditioning; Umbilical cord blood

Mesh:

Substances:

Year:  2015        PMID: 25708220     DOI: 10.1016/j.bbmt.2015.02.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

Review 1.  Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!

Authors:  Tamila L Kindwall-Keller; Karen K Ballen
Journal:  Oncologist       Date:  2017-05-25

2.  Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Authors:  Iskra Pusic; Jaebok Choi; Mark A Fiala; Feng Gao; Matthew Holt; Amanda F Cashen; Ravi Vij; Camille N Abboud; Keith E Stockerl-Goldstein; Meghan A Jacoby; Geoffrey L Uy; Peter Westervelt; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-05       Impact factor: 5.742

Review 3.  Unrelated cord blood transplantation versus haploidentical transplantation in adult and pediatric patients with hematological malignancies-A meta-analysis and systematic review.

Authors:  Duihong Li; Xiaofan Li; Lianming Liao; Nainong Li
Journal:  Am J Blood Res       Date:  2020-02-15

4.  [Effect of cyclophosphamide on hematopoietic stem cells in mice with iron overload].

Authors:  Yanjun Xu; Tiantian Yi; Xiaoxiao Xu; Fuyu Pei; Yuelin He; Xuedong Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

5.  Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation.

Authors:  Giancarlo Fatobene; Barry E Storer; Rachel B Salit; Stephanie J Lee; Paul J Martin; Guang-Shing Cheng; Paul A Carpenter; Gansuvd Balgansuren; Effie W Petersdorf; Colleen Delaney; Brenda M Sandmaier; Filippo Milano; Mary E Flowers
Journal:  Haematologica       Date:  2018-11-15       Impact factor: 9.941

Review 6.  Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.

Authors:  Marzieh Nikoo; Mohammad Rudiansyah; Dmitry Olegovich Bokov; Nurlan T Jainakbaev; Wanich Suksatan; Mohammad Javed Ansari; Lakshmi Thangavelu; Supat Chupradit; Amir Zamani; Ali Adili; Navid Shomali; Morteza Akbari
Journal:  J Cell Mol Med       Date:  2022-06-28       Impact factor: 5.295

Review 7.  Alternative Donor Transplantation for Acute Myeloid Leukemia.

Authors:  Nelli Bejanyan; Housam Haddad; Claudio Brunstein
Journal:  J Clin Med       Date:  2015-06-09       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.